Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1967 1
1971 1
1977 2
1978 2
1980 3
1981 1
1982 1
1983 2
1985 3
1986 2
1987 1
1988 2
1989 6
1990 3
1991 2
1992 3
1994 4
1995 6
1996 1
1998 1
1999 1
2000 4
2001 2
2002 3
2003 2
2004 2
2005 3
2006 3
2007 3
2008 3
2009 1
2010 2
2011 1
2012 1
2013 2
2016 3
2017 3
2018 1
2019 2
2020 2
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Sideroblastic anemia 3"
Page 1
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Fenaux P, et al. N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892. N Engl J Med. 2020. PMID: 31914241 Free article. Clinical Trial.
BACKGROUND: Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor …
BACKGROUND: Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not eff …
Heme biosynthesis and the porphyrias.
Phillips JD. Phillips JD. Mol Genet Metab. 2019 Nov;128(3):164-177. doi: 10.1016/j.ymgme.2019.04.008. Epub 2019 Apr 22. Mol Genet Metab. 2019. PMID: 31326287 Free PMC article. Review.
In each porphyria the distinct patterns of these substances in plasma, erythrocytes, urine and feces are the basis for diagnostically defining the metabolic defect underlying the clinical observations. Porphyrias may also be classified as either erythropoietic or hepatic, …
In each porphyria the distinct patterns of these substances in plasma, erythrocytes, urine and feces are the basis for diagnostically defini …
Copper deficiency in humans.
Williams DM. Williams DM. Semin Hematol. 1983 Apr;20(2):118-28. Semin Hematol. 1983. PMID: 6410510 Review.
Metabolic balance studies have demonstrated that daily copper losses are approximately 1.3 mg/day. In order to remain in copper balance, the average adult male must consume a diet which contains at least 2 mg copper/day. ...Sideroblastic changes as well as nuclear m …
Metabolic balance studies have demonstrated that daily copper losses are approximately 1.3 mg/day. In order to remain in copper balan …
Antioxidant defense mechanisms and its dysfunctional regulation in the mitochondrial disease, Friedreich's ataxia.
Chiang S, Huang MLH, Park KC, Richardson DR. Chiang S, et al. Free Radic Biol Med. 2020 Nov 1;159:177-188. doi: 10.1016/j.freeradbiomed.2020.07.019. Epub 2020 Jul 30. Free Radic Biol Med. 2020. PMID: 32739593 Review.
There are a number of disease states, including Friedreich's ataxia (FA) and sideroblastic anemia, where iron metabolism is dysregulated and leads to mitochondrial iron accumulation. ...Instead, it forms unbound biomineral aggregates composed of high spin iron(III), …
There are a number of disease states, including Friedreich's ataxia (FA) and sideroblastic anemia, where iron metabolism is dy …
Clinical Features, Molecular Heterogeneity, and Prognostic Implications in YARS2-Related Mitochondrial Myopathy.
Sommerville EW, Ng YS, Alston CL, Dallabona C, Gilberti M, He L, Knowles C, Chin SL, Schaefer AM, Falkous G, Murdoch D, Longman C, de Visser M, Bindoff LA, Rawles JM, Dean JCS, Petty RK, Farrugia ME, Haack TB, Prokisch H, McFarland R, Turnbull DM, Donnini C, Taylor RW, Gorman GS. Sommerville EW, et al. JAMA Neurol. 2017 Jun 1;74(6):686-694. doi: 10.1001/jamaneurol.2016.4357. JAMA Neurol. 2017. PMID: 28395030 Free PMC article.
IMPORTANCE: YARS2 mutations have been associated with a clinical triad of myopathy, lactic acidosis, and sideroblastic anemia in predominantly Middle Eastern populations. However, the identification of new patients expands the clinical and molecular spectrum of mito …
IMPORTANCE: YARS2 mutations have been associated with a clinical triad of myopathy, lactic acidosis, and sideroblastic anemia …
The role of vitamins in the prevention and control of anaemia.
Fishman SM, Christian P, West KP. Fishman SM, et al. Public Health Nutr. 2000 Jun;3(2):125-50. doi: 10.1017/s1368980000000173. Public Health Nutr. 2000. PMID: 10948381 Review.
Vitamin E supplementation given to preterm infants has not reduced the severity of the anaemia of prematurity. Vitamin B6 effectively treats sideroblastic anaemia. Multivitamin supplementation may raise haemoglobin (Hb) concentration, but few studies have isolated t …
Vitamin E supplementation given to preterm infants has not reduced the severity of the anaemia of prematurity. Vitamin B6 effectively treats …
Clinical Application for Diagnosis of Myelodysplatic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis.
Lee MY, Jang S, Park CJ, Cho YU. Lee MY, et al. Clin Lab. 2022 Apr 1;68(4). doi: 10.7754/Clin.Lab.2021.210738. Clin Lab. 2022. PMID: 35443589
METHODS: We reviewed the bone marrow and genetic studies of patients whose diagnoses were coded as "refractory anemia with ring sideroblasts (RARS)" or "MDS/MPN, unclassifiable" between January 2008 and April 2018. ...JAK2 mutation tests were performed in 7 cases, and a he …
METHODS: We reviewed the bone marrow and genetic studies of patients whose diagnoses were coded as "refractory anemia with ring sider …
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.
Patnaik MM, Tefferi A. Patnaik MM, et al. Am J Hematol. 2017 Mar;92(3):297-310. doi: 10.1002/ajh.24637. Am J Hematol. 2017. PMID: 28188970 Free PMC article. Review.
RISK STRATIFICATION: Most patients with MDS-RS-SLD are stratified into lower risk groups by the revised-International Prognostic Scoring System (R-IPSS). Disease outcome in MDS/MPN-RS-T is better than that of MDS-RS-SLD, but worse than that of essential thrombocythe …
RISK STRATIFICATION: Most patients with MDS-RS-SLD are stratified into lower risk groups by the revised-International Prognostic Scoring …
Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases.
Ramos-Casals M, García-Carrasco M, López-Medrano F, Trejo O, Forns X, López-Guillermo A, Muñoz C, Ingelmo M, Font J. Ramos-Casals M, et al. Medicine (Baltimore). 2003 Mar;82(2):87-96. doi: 10.1097/00005792-200303000-00003. Medicine (Baltimore). 2003. PMID: 12640185 Free article. Review.
We identified the following cytopenias: AHA (17 cases), severe thrombocytopenia (16 cases), aplastic anemia (2 cases), severe neutropenia (1 case), refractory sideroblastic anemia (1 case), and pure red cell aplasia (1 case). ...The 35 cases presented demonst …
We identified the following cytopenias: AHA (17 cases), severe thrombocytopenia (16 cases), aplastic anemia (2 cases), severe neutrop …
Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.
Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S. Moyo V, et al. Ann Hematol. 2008 Jul;87(7):527-36. doi: 10.1007/s00277-008-0450-7. Epub 2008 Mar 20. Ann Hematol. 2008. PMID: 18351340 Review.
The present meta-analysis was undertaken to (1) assess erythroid response rates in myelodysplastic syndromes (MDS) patients treated with epoetin alfa as a monotherapy, (2) gain further insights into predictors of response rates, and (3) compare the erythroid respons …
The present meta-analysis was undertaken to (1) assess erythroid response rates in myelodysplastic syndromes (MDS) patients treated with epo …
92 results